Table 5.
Univariate and multivariate analyses of the prognostic factors of overall survival (OS) in the validation cohort.
| Variables | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P value | HR | 95% CI | P- value | |
| Age, years (<55/≥55) | 1.029 | 0.774-1.368 | 0.388 | |||
| Gender (Male/Female) | 1.044 | 0.853-1.277 | 0.876 | |||
| ECOG PS score (0/1-2) | 1.248 | 0.939-1.658 | 0.127 | |||
| Primary tumor site ( Left /Right ) | 1.072 | 0.749-1.533 | 0.705 | |||
| Tumor grade (G1-2/G3) | 1.475 | 1.059-2.056 | 0.022 | 1.635 | 1.163-2.300 | 0.005 |
| Number of metastatic organs (1/≥2) | 0.886 | 0.669-1.173 | 0.397 | |||
| Primary/Metastatic tumor resection (Yes/No) | 1.087 | 0.822-1.438 | 0.559 | |||
| Chemotherapy (Chemo/combination) | 0.970 | 0.706-1.333 | 0.852 | |||
| CEA (ng/ml) (<5/≥5) | 1.605 | 1.170-2.203 | 0.003 | 1.441 | 1.029-2.016 | 0.033 |
| CA19-9 (ng/ml) (<35/≥35) | 1.664 | 1.251-2.214 | < 0.001 | 1.489 | 1.101-2.015 | 0.010 |
| Cholesterols (mmol/L) (≤6.47/>6.47) | 0.955 | 0.618-1.477 | 0.855 | |||
| Triglycerides (mmol/L) (≤1.70/>1.70) | 1.208 | 0.872-1.673 | 0.256 | |||
| HDL-C (mmol/L) (≥0.78/<0.78) | 1.424 | 0.947-2.140 | 0.089 | |||
| LDL-C (mmol/L) (≤3.40/>3.40) | 1.298 | 0.996-1.726 | 0.072 | |||
| ApoA-I (ng/L) (≥1.05/<1.05) | 1.391 | 1.040-1.863 | 0.026 | |||
| ApoB (ng/L) (≤1.15/>1.15) | 1.356 | 1.005-1.861 | 0.046 | |||
| LDL-C/HDL-C (<2.55/≥2.55) | 1.491 | 1.107-2.009 | 0.008 | |||
| ApoB/ApoA-I (<0.69/≥0.69) | 2.122 | 1.504-2.995 | < 0.001 | 1.924 | 1.360-2.723 | <0.001 |
*ECOG PS score: Eastern Cooperative Oncology Group performance status score; CEA: serum carcinoembryonic antigen; CA19-9: carbohydrate antigen 19-9; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; ApoA-I: apolipoprotein A-I; ApoB: apolipoprotein B; LDL-C/HDL-C: LDL-C to HDL-C ratio; ApoB/ApoA-I: ApoB to ApoA-I ratio.